227 related articles for article (PubMed ID: 24626333)
1. Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells.
Labsch S; Liu L; Bauer N; Zhang Y; Aleksandrowicz E; Gladkich J; Schönsiegel F; Herr I
Int J Oncol; 2014 May; 44(5):1470-80. PubMed ID: 24626333
[TBL] [Abstract][Full Text] [Related]
2. Dietary polyphenol quercetin targets pancreatic cancer stem cells.
Zhou W; Kallifatidis G; Baumann B; Rausch V; Mattern J; Gladkich J; Giese N; Moldenhauer G; Wirth T; Büchler MW; Salnikov AV; Herr I
Int J Oncol; 2010 Sep; 37(3):551-61. PubMed ID: 20664924
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
Rausch V; Liu L; Kallifatidis G; Baumann B; Mattern J; Gladkich J; Wirth T; Schemmer P; Büchler MW; Zöller M; Salnikov AV; Herr I
Cancer Res; 2010 Jun; 70(12):5004-13. PubMed ID: 20530687
[TBL] [Abstract][Full Text] [Related]
4. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells.
Li Y; Zhang T; Korkaya H; Liu S; Lee HF; Newman B; Yu Y; Clouthier SG; Schwartz SJ; Wicha MS; Sun D
Clin Cancer Res; 2010 May; 16(9):2580-90. PubMed ID: 20388854
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.
Bergantin E; Quarta C; Nanni C; Fanti S; Pession A; Cantelli-Forti G; Tonelli R; Hrelia P
Cancer Biol Ther; 2014 Sep; 15(9):1219-25. PubMed ID: 24971463
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition.
Appari M; Babu KR; Kaczorowski A; Gross W; Herr I
Int J Oncol; 2014 Oct; 45(4):1391-400. PubMed ID: 25017900
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate.
Kallifatidis G; Labsch S; Rausch V; Mattern J; Gladkich J; Moldenhauer G; Büchler MW; Salnikov AV; Herr I
Mol Ther; 2011 Jan; 19(1):188-95. PubMed ID: 20940707
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling.
Kallifatidis G; Rausch V; Baumann B; Apel A; Beckermann BM; Groth A; Mattern J; Li Z; Kolb A; Moldenhauer G; Altevogt P; Wirth T; Werner J; Schemmer P; Büchler MW; Salnikov AV; Herr I
Gut; 2009 Jul; 58(7):949-63. PubMed ID: 18829980
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
13. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
14. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Shankar S; Ganapathy S; Srivastava RK
Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5.
Kim H; Kim EH; Eom YW; Kim WH; Kwon TK; Lee SJ; Choi KS
Cancer Res; 2006 Feb; 66(3):1740-50. PubMed ID: 16452234
[TBL] [Abstract][Full Text] [Related]
17. TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells.
Jin CY; Molagoda IMN; Karunarathne WAHM; Kang SH; Park C; Kim GY; Choi YH
Toxicol Appl Pharmacol; 2018 Aug; 352():132-141. PubMed ID: 29792947
[TBL] [Abstract][Full Text] [Related]
18. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
Szliszka E; Helewski KJ; Mizgala E; Krol W
Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
[TBL] [Abstract][Full Text] [Related]
19. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
[TBL] [Abstract][Full Text] [Related]
20. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.
Civenni G; Longoni N; Costales P; Dallavalle C; García Inclán C; Albino D; Nuñez LE; Morís F; Carbone GM; Catapano CV
Mol Cancer Ther; 2016 May; 15(5):806-18. PubMed ID: 26826115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
